Tests and investigations for colorectal cancer screening

Clinical Biochemistry

Volumn 47, Issue 10-11, 2014, Pages 921-939

  Carroll, Magdalen R R ^a,b   Seaman, Helen E ^a,b,c   Halloran, Stephen P ^a,b,c  

^a NHS Bowel Cancer Screening Southern Programme Hub   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Bowel; Cancer; Colorectal; Faecal immunochemical test; Faecal occult blood; FIT; FOBT; Screening

Indexed keywords

BIOLOGICAL MARKER; GUAIAC; HEMOGLOBIN;

ARTICLE; BARIUM ENEMA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CAPSULE ENDOSCOPY; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; DOUBLE CONTRAST BARIUM ENEMA; FLEXIBLE SIGMOIDOSCOPY; HUMAN; LABORATORY TEST; OCCULT BLOOD TEST; PRIORITY JOURNAL; SCREENING TEST; SIGMOIDOSCOPY;

EID: 84903256473     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.04.019     Document Type: Article

References (218)

1. Ferlay J.S.H., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2008, 127:2893-2917.
2. Organisation for Economic Co-operation and Development Health at a glance 2013: OECD Indicators 2013.
3. UK Cancer Research Bowel cancer mortality statistics 2013, Cancer Research UK, [Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/mortality/. Accessed: 16-12-2013].
4. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. [Epub 2011/02/08].
5. Brenner H., Hoffmeister M., Arndt V., Haug U. Gender differences in colorectal cancer: implications for age at initiation of screening. Br J Cancer 2007, 96:828-831.
6. World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) Food, nutrition, physical activity and prevention of cancer: a global perspective 2007, [Washington DC].
7. Warburton D., Charlesworth S., Ivey A., Nettlefold L., Bredin S. A systematic review of the evidence for Canada's Physical Activity Guidelines for Adults. Int J Behav Nutr Phys Act 2010, 7:39. [Epub May 11th 2010].
8. Hannan L.M., Jacobs E.J., Thun M.J. The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. Cancer Epidemiol Biomarkers Prev 2009, 18(12):3362-3367. [Epub 2009/12/05].
9. Gong J., Hutter C., Baron J.A., Berndt S., Caan B., Campbell P.T., et al. A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. Cancer Epidemiol Biomarkers Prev 2012, 21(11):1974-1985. [Epub 2012/09/25].
10. Park Y., Hunter D.J., Spiegelman D., Bergkvist L., Berrino F., van den Brandt P.A., et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 2005, 294(22):2849-2857. [Epub 2005/12/15].
11. Parkin D.M. 5. Cancers attributable to dietary factors in the UK in 2010. Br J Cancer 2011, 105:s24-S6.
12. Kim J.H., Lim Y.J., Kim Y.H., Sung I.K., Shim S.G., Oh S.O., et al. Is metabolic syndrome a risk factor for colorectal adenoma?. Cancer Epidemiol Biomarkers Prev 2007, 16(8):1543-1546. [Epub 2007/08/09].
13. Yuhara H., Steinmaus C., Cohen S.E., Corley D.A., Tei Y., Buffler P.A. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. Am J Gastroenterol 2011, 106(11):1911-1921. [Epub 2011/09/14].
14. Fearnhead N.S., Wilding J.L., Bodmer W.F. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 2002, 64:27-43. [Epub 2002/11/08].
15. Fuchs C.S., Giovannucci E.L., Colditz G.A., Hunter D.J., Speizer F.E., Willett W.C. A Prospective Study of Family History and the Risk of Colorectal Cancer. N Engl J Med 1994, 331(25):1669-1674.
16. Lynch H.T., Lynch J.F. What the physician needs to know about Lynch syndrome: an update. Oncology (Williston Park) 2005, 19(4):455-463. [discussion 63-4, 66, 69. Epub 2005/06/09].
17. Lynch H.T., Rubinstein W.S., Locker G.Y. Cancer in Jews: introduction and overview. Fam Cancer 2004, 3(3-4):177-192. [Epub 2004/11/02].
18. Goldberg Y., Kedar I., Kariiv R., Halpern N., Plesser M., Hubert A., et al. Lynch Syndrome in high risk Ashkenazi Jews in Israel. Fam Cancer 2014, 13(1):65-73. [Epub 2013/08/31].
19. Boparai K.S., Mathus-Vliegen E.M., Koornstra J.J., Nagengast F.M., van Leerdam M., van Noesel C.J., et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut 2010, 59(8):1094-1100. [Epub 2009/08/28].
20. Center M.M., Jemal A., Smith R.A., Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009, 59(6):366-378. [Epub 2009/11/10].
21. Autier P., Ait Ouakrim D., Malvezzi M., Bleiberg H., Jenkins M., Boniol M., et al. Trends in colorectal cancer mortality and screening activities in European countries. The European Cancer Congress 2013 2013, [Amsterdam].
22. Wilson J., Jungner G. Principles and practice of screening for disease. Public Health Papers No. 34 1968, WHO, Geneva.
23. UK National Screening Committee Criteria for appraising the viability, effectiveness and appropriateness of a screening programme Available from:, [Accessed: 27/09/2013]. http://www.screening.nhs.uk/criteria.
24. Hardcastle J.D., Chamberlain J.O., Robinson M.H., Moss S.M., Amar S.S., Balfour T.W., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348(9040):1472-1477. [Epub 1996/11/30].
25. Kronborg O., Fenger C., Olsen J., Jorgensen O.D., Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348(9040):1467-1471.
26. Kewenter J., Brevinge H., Engaras B., Haglind E., Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 1994, 29(5):468-473.
27. Mandel J.S., Bond J.H., Church T.R., Snover D.C., Bradley G.M., Schuman L.M., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control. N Engl J Med 1993, 328(19):1365-1371.
28. Hewitson P., Glasziou P., Watson E., Towler B., Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008, 103(6):1541-1549. [Epub 2008/05/16].
29. Shaukat A., Mongin S.J., Geisser M.S., Lederle F.A., Bond J.H., Mandel J.S., et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013, 369(12):1106-1114.
30. Faivre J., Dancourt V., Lejeune C., Tazi M.A., Lamour J., Gerard D., et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004, 126(7):1674-1680.
31. Scholefield J.H., Moss S.M., Mangham C.M., Whynes D.K., Hardcastle J.D. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012, 61(7):1036-1040. [Epub 2011/11/05].
32. National Cancer Institute SEER Cancer Statistics Review, 1975-2004 2007, [Bethesda, MD].
33. Zauber A.G., Winawer S.J., O'Brien M.J., Lansdorp-Vogelaar I., van Ballegooijen M., Hankey B.F., et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012, 366(8):687-696.
34. Scholefield J.H. Screening for colorectal cancer. Br Med Bull 2002, 64(1):75-80.
35. Winawer S.J., Fletcher R.H., Miller L., Godlee F., Stolar M.H., Mulrow C.D., et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997, 112(2):594-642.
36. Williams A., Balasooriya B., Day D. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982, 23:835-842.
37. Brenner H., Hoffmeister M., Stegmaier C., Brenner G., Altenhofen L., Haug U. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840 149 screening colonoscopies. Gut 2007, 56(11):1585-1589.
38. Muto T., Bussey H.J., Morson B.C. The evolution of cancer of the colon and rectum. Cancer 1975, 36(6):2251-2270. [Epub 1975/12/01].
39. Tsai C.J., Lu D.K. Small colorectal polyps: histopathology and clinical significance. Am J Gastroenterol 1995, 90(6):988-994. [Epub 1995/06/01].
40. Rondagh E.J., Gulikers S., Gomez-Garcia E.B., Vanlingen Y., Detisch Y., Winkens B., et al. Nonpolypoid colorectal neoplasms: a challenge in endoscopic surveillance of patients with Lynch syndrome. Endoscopy 2013, 45(4):257-264. [Epub 2013/02/27].
41. Church J. Complications of colonoscopy. Gastroenterol Clin North Am 2013, 42(3):639-657. [Epub 2013 Jun 28].
42. Singh A., Kuo Y.F., Riall T.S., Raju G.S., Goodwin J.S. Predictors of colorectal cancer following a negative colonoscopy in the Medicare population. Dig Dis Sci 2011, 56(11):3122-3128. [Epub 2011/06/18].
43. Barclay R.L., Vicari J.J., Doughty A.S., Johanson J.F., Greenlaw R.L. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006, 355(24):2533-2541. [Epub 2006/12/15].
44. Joint Advisory Group on GI Endoscopy BCSP Guidelines - Accreditation of screening colonoscopists. Royal College of Physicians 2011.
45. Rex D.K., Johnson D.A., Anderson J.C., Schoenfeld P.S., Burke C.A., Inadomi J.M. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009, 104(3):739-750. [Epub 2009/02/26].
46. von Karsa L., Patnick J., Segnan N., Atkin W., Halloran S., Lansdorp-Vogelaar I., et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013, 45(1):51-59. [Epub 2012/12/06].
47. Lieberman D.A., Rex D.K., Winawer S.J., Giardiello F.M., Johnson D.A., Levin T.R. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012, 143(3):844-857.
48. Chilton A., Rutter M. Quality Assurance Guidelines for Colonoscopy. NHS Cancer Screening Programmes (NHS Bowel Cancer Screening Programme, Publication No 6) 2011.
49. Cairns S.R., Scholefield J.H., Steele R.J., Dunlop M.G., Thomas H.J., Evans G.D., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010, 59(5):666-689. [Epub 2010/04/30].
50. Sewitch M.J., Fournier C., Ciampi A., Dyachenko A. Adherence to colorectal cancer screening guidelines in Canada. BMC Gastroenterol 2007, 7:39.
51. Panteris V., Haringsma J., Kuipers E.J. Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy. Endoscopy 2009, 41(11):941-951. [Epub 2009/10/30].
52. Brenner H., Altenhofen L., Hoffmeister M. Eight Years of Colonoscopic Bowel Cancer Screening in Germany: Initial Findings and Projections. Dtsch Arztebl Int 2010, 107(43):753-759.
53. Atkin W.S., Cook C.F., Cuzick J., Edwards R., Northover J.M., Wardle J. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002, 359(9314):1291-1300. [Epub 2002/04/20].
54. Cappell M.S. The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Med Clin North Am 2005, 89(1):1-42. [Epub 2004/11/06].
55. Atkin W.S., Edwards R., Kralj-Hans I., Wooldrage K., Hart A.R., Northover J.M., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375(9726):1624-1633.
56. Schoen R.E., Pinsky P.F., Weissfeld J.L., Yokochi L.A., Church T., Laiyemo A.O., et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012, 366(25):2345-2357.
57. National Cancer Institute Protocol for the National Cancer Institute Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial. Version 13 Available from:, [Accessed: 27-01-2014]. http://www.nejm.org/doi/suppl/10.1056/NEJMoa1114635/suppl_file/nejmoa1114635_protocol.pdf.
58. Atkin W., Dadswell E., Wooldrage K., Kralj-Hans I., von Wagner C., Edwards R., et al. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet 2013, 381(9873):1194-1202. [Epub 2013/02/19].
59. Stoop E.M., de Haan M.C., de Wijkerslooth T.R., Bossuyt P.M., van Ballegooijen M., Nio C.Y., et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2012, 13(1):55-64. [Epub 2011/11/18].
60. Plumb A.A., Halligan S., Nickerson C., Bassett P., Goddard A.F., Taylor S.A., et al. Use of CT colonography in the English Bowel Cancer Screening Programme. Gut 2014, 63(6):964-973. [Epub 2013/08/21].
61. Hassan C., Zullo A., Winn S., Morini S. Cost-effectiveness of capsule endoscopy in screening for colorectal cancer. Endoscopy 2008, 40(5):414-421. [Epub 2008/02/28].
62. Sieg A., Friedrich K., Sieg U. Is PillCam COLON capsule endoscopy ready for colorectal cancer screening? A prospective feasibility study in a community gastroenterology practice. Am J Gastroenterol 2009, 104(4):848-854. [Epub 2009/02/26].
63. Halligan S., Wooldrage K., Dadswell E., Kralj-Hans I., von Wagner C., Edwards R., et al. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet 2013, 381(9873):1185-1193. [Epub 2013/02/19].
64. Winawer S.J., Stewart E.T., Zauber A.G., Bond J.H., Ansel H., Waye J.D., et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000, 342(24):1766-1772. [Epub 2000/06/15].
65. Segnan N., Armaroli P., Bonelli L., Risio M., Sciallero S., Zappa M., et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst 2011, 103(17):1310-1322. [Epub 2011/08/20].
66. Nishihara R., Wu K., Lochhead P., Morikawa T., Liao X., Qian Z.R., et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013, 369(12):1095-1105.
67. Kaminski M.F., Bretthauer M., Zauber A.G., Kuipers E.J., Adami H.O., van Ballegooijen M., et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 2012, 44(7):695-702. [Epub 2012/06/23].
68. de Haan M.C., van Gelder R.E., Graser A., Bipat S., Stoker J. Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis. Eur Radiol 2011, 21(8):1747-1763. [Epub 2011/04/02].
69. Whitlock E.P., Lin J.S., Liles E., Beil T.L., Fu R. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008, 149(9):638-658.
70. de Wijkerslooth T.R., de Haan M.C., Stoop E.M., Bossuyt P.M., Thomeer M., Essink-Bot M.-L., et al. Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial. Gut 2012, 61(11):1552-1559. [Epub 2011 Dec 23].
71. Van Gossum A., Munoz-Navas M., Fernandez-Urien I., Carretero C., Gay G., Delvaux M., et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009, 361(3):264-270. [Epub 2009/07/17].
72. Eliakim R., Yassin K., Niv Y., Metzger Y., Lachter J., Gal E., et al. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. Endoscopy 2009, 41(12):1026-1031. [Epub 2009/12/08].
73. Lansdorp-Vogelaar I., Knudsen A.B., Brenner H. Cost-effectiveness of Colorectal Cancer Screening. Epidemiol Rev 2011, 33(1):88-100.
74. Halloran S.P., Launoy G., Zappa M. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition Faecal occult blood testing. Endoscopy 2012, 44(S 03):SE65-SE87.
75. Di Lena M., Travaglio E., Altomare D.F. New strategies for colorectal cancer screening. World J Gastroenterol 2013, 19(12):1855-1860. [Epub 2013/04/10].
76. Cheng Y., Xie G., Chen T., Qiu Y., Zou X., Zheng M., et al. Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res 2012, 11(2):1354-1363. [Epub 2011/12/14].
77. Peng G., Hakim M., Broza Y.Y., Billan S., Abdah-Bortnyak R., Kuten A., et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer 2010, 103(4):542-551. [Epub 2010/07/22].
78. Sonoda H., Kohnoe S., Yamazato T., Satoh Y., Morizono G., Shikata K., et al. Colorectal cancer screening with odour material by canine scent detection. Gut 2011, 60(6):814-819. [Epub 2011/02/02].
79. Altomare D.F., Di Lena M., Porcelli F., Trizio L., Travaglio E., Tutino M., et al. Exhaled volatile organic compounds identify patients with colorectal cancer. Br J Surg 2013, 100(1):144-150.
80. Holten-Andersen L., Christensen I.J., Jensen S.B., Reibel J., Laurberg S., Nauntofte B., et al. Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study. Scand J Gastroenterol 2012, 47(10):1234-1241. [Epub 2012/08/09].
81. Moore R.A., Derry S., McQuay H.J. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther 2008, 10(1):R7.
82. Fraser C.G., Matthew C.M., McKay K., Carey F.A., Steele R.J.C. Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut 2008, 57(9):1256-1260.
83. Levi Z., Rozen P., Hazazi R., Vilkin A., Waked A., Maoz E., et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007, 146(4):244-255. [Epub 2007/02/21].
84. Ciatto S., Martinelli F., Castiglione G., Mantellini P., Rubeca T., Grazzini G., et al. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 2007, 96(2):218-221. [Epub 2007/01/11].
85. Chen L.S., Yen A.M., Chiu S.Y., Liao C.S., Chen H.H. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011, 12(6):551-558. [Epub 2011/05/20].
86. Greegor D.H. Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA 1967, 201:943-945.
87. Allison J.E. The Role of Fecal Occult Blood Testing in Screening for Colorectal Cancer. Pract Gastroenterol 2007, 31(6):20-32.
88. Deutekom M., van Rossum L.G., van Rijn A.F., Laheij R.J., Fockens P., Bossuyt P.M., et al. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective. Scand J Gastroenterol 2010, 45(11):1345-1349. [Epub 2010/06/22].
89. Feinberg E.J., Steinberg W.M., Banks B.L., Henry J.P. How long to abstain from eating red meat before fecal occult blood tests. Ann Intern Med 1990, 113(5):403-404.
90. Sinatra M.A., St John D.J., Young G.P. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Clin Chem 1999, 45(1):123-126. [Epub 1999/01/23].
91. Cole S.R., Young G.P. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001, 175(4):195-198.
92. Pignone M., Campbell M.K., Carr C., Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001, 4(4):150-156. [Epub 2001/08/30].
93. Konrad G. Dietary interventions for fecal occult blood test screening: systematic review of the literature. Can Fam Physician 2010, 56(3):229-238. [Epub 2010/03/17].
94. Bini E.J., Rajapaksa R.C., Weinshel E.H. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol 2005, 100(7):1586-1592.
95. Clarke P., Jack F., Carey F.A., Steele R.J. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis 2006, 8(5):389-392.
96. Greenberg P.D., Cello J.P., Rockey D.C. Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc 1999, 50(5):618-622.
97. Kahi C.J., Imperiale T.F. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med 2004, 117(11):837-841.
98. Konrad G., Katz A. Are medication restrictions before FOBT necessary?: Practical advice based on a systematic review of the literature. Can Fam Physician 2012, 58(9):939-948.
99. Young G.P. Fecal immunochemical tests (FIT) vs. office-based guaiac-fecal occult blood test (FOBT). Pract Gastroenterol 2004, 28(6):46-56.
100. Fleisher M., Winawer S.J., Zauber A.G., Smith C., Schwartz M.K. Accuracy of fecal occult blood test interpretation. National Polyp Study Work Group. Ann Intern Med 1991, 114(10):875-876.
101. Selinger R.R., Norman S., Dominitz J.A. Failure of health care professionals to interpret fecal occult blood tests accurately. Am J Med 2003, 114(1):64-67.
102. Burtonwood C., Butler P., Young M., Halloran S. PWE-091 Monitoring faecal occult blood test positivity in the NHS bowel cancer screening programme. Gut 2012, 61(Suppl. 2):A334.
103. Logan R.F.A., Patnick J., Nickerson C., Coleman L., Rutter M.D., von Wagner C. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 2012, 61(10):1439-1446. [Epub 2011 Dec 7].
104. Geraghty J., Snowball J., Butler P., Sarkar S., Blanks R., Halloran S., et al. OC-083. Faecal Occult Blood test Analysis in the United Kingdom Bowel Cancer Screening Programme. Gut 2013, 62(Suppl. 1):A36.
105. Moss S.M., Campbell C., Melia J., Coleman D., Smith S., Parker R., et al. Performance measures in three rounds of the English bowel cancer screening pilot. Gut 2012, 61(1):101-107.
106. Duffy M.J., van Rossum L.G., van Turenhout S.T., Malminiemi O., Sturgeon C., Lamerz R., et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011, 128(1):3-11. [Epub 2010/09/09].
107. Allison J.E., Tekawa I.S., Ransom L.J., Adrain A.L. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996, 334(3):155-159. [Epub 1996/01/18].
108. Hoffman R.M., Steel S., Yee E.F., Massie L., Schrader R.M., Murata G.H. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev Med 2010, 50(5-6):297-299. [Epub 2010/03/24].
109. Vart G., Banzi R., Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med 2012, 55(2):87-92. [Epub 2012/05/29].
110. Rabeneck L., Rumble R.B., Thompson F., Mills M., Oleschuk C., Whibley A., et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012, 26(3):131-147. [Epub 2012/03/13].
111. Hughes K., Leggett B., Del Mar C., Croese J., Fairley S., Masson J., et al. Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community. Aust N Z J Public Health 2005, 29(4):358-364. [Epub 2005/10/15].
112. van Rossum L.G., van Rijn A.F., Laheij R.J., van Oijen M.G., Fockens P., van Krieken H.H., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008, 135(1):82-90. [Epub 2008/05/17].
113. Hol L., van Leerdam M.E., van Ballegooijen M., van Vuuren A.J., van Dekken H., Reijerink J.C., et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010, 59(1):62-68. [Epub 2009/08/13].
114. Digby J., McDonald P.J., Strachan J.A., Libby G., Steele R.J., Fraser C.G. Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme. J Med Screen 2013, 20(2):80-85. [Epub 2013/09/07].
115. Carroll M.R.R., Piggott C., Pearson S., Seaman H.E., Halloran S.P. Evaluation of quantitative faecal immunochemical tests for haemoglobin 2013, Guildford Medical Device Evaluation Centre (GMEC), Guildford, UK, [Available at: http://www.worldendo.org/assets/downloads/pdf/activities/fit_reports/gmec_fit_evaluation_report.pdf].
116. Lamph SA B.W., Brannon C.R., Halloran S.P. Evaluation Report: Immunochemical faecal occult blood tests 2009, NHS Purchasing & Supply Agency, Centre for Evidence-based Purchasing, [Contract No.: CEP09042].
117. Allison J.E., Fraser C.G., Halloran S.P., Young G.P. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology 2012, 142(3):422-424. [Epub 2012/01/24].
118. Fraser C.G., Allison J.E., Young G.P., Halloran S. Newer fecal tests: opportunities for professionals in laboratory medicine. Clin Chem 2012, 58(6):963-965. [Epub 27 March 2012].
119. Fraser C.G., Allison J.E., Halloran S.P., Young G.P. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 2012, 104(11):810-814. [Epub 2012/04/05].
120. Young G.P., Fraser C.G., Halloran S.P., Cole S. Guaiac based faecal occult blood testing for colorectal cancer screening: an obsolete strategy?. Gut 2012, 61(7):959-960.
121. Fraser C., Halloran S., Allison J., Young G. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT). Clin Chem Lab Med 2013, 51(11):2065-2067.
122. Fraser C.G., Allison J.E., Young G.P., Halloran S.P. Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Clin Gastroenterol Hepatol 2013, 11(7):839-840. [Epub 2013 Apr 13].
123. Allison J.E., Fraser C.G., Halloran S.P., Young G.P. Population screening for colorectal cancer means getting FIT. The past, present, and future of colorectal cancer screening using FIT. Gut Liver 2014, 8:117-130.
124. Fraser C.G., Allison J.E., Young G.P., Halloran S.P., Seaman H.E. A Standard for Faecal Immunochemical TesTs for Haemoglobin Evaluation Reporting (FITTER) (Letter). Ann Clin Biochem 2014, 51(2):301-302. [Epub ahead of print].
125. Fraser C.G., Allison J.E., Young G.P., Halloran S.P., Seaman H.E. Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. Eur J Cancer Prev 2014, [Epub 27 February 2014].
126. Bulliard J.L., Garcia M., Blom J., Senore C., Mai V., Klabunde C. Sorting out measures and definitions of screening participation to improve comparability: The example of colorectal cancer. Eur J Cancer 2014, 50(2):434-446. [Epub 2013/10/18].
127. Hol L., Kuipers E.J., van Ballegooijen M., van Vuuren A.J., Reijerink J.C., Habbema D.J., et al. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer 2012, 130(9):2096-2102. [Epub 2011/06/28].
128. Senore C., Ederle A., Benazzato L., Arrigoni A., Silvani M., Fantin A., et al. Offering people a choice for colorectal cancer screening. Gut 2013, 62(5):735-740.
129. Quintero E., Castells A., Bujanda L., Cubiella J., Salas D., Lanas Á., et al. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. N Engl J Med 2012, 366(8):697-706.
130. Gupta S., Halm E.A., Rockey D.C., Hammons M., Koch M., Carter E., et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med 2013, 173(18):1725-1732. [Epub 2013/08/08].
131. Park D.I., Ryu S., Kim Y.H., Lee S.H., Lee C.K., Eun C.S., et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010, 105(9):2017-2025. [Epub 2010/05/27].
132. de Wijkerslooth T.R., Stoop E.M., Bossuyt P.M., Meijer G.A., van Ballegooijen M., van Roon A.H., et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012, 107:1570-1578. [Epub 2012/08/02].
133. Haug U., Kuntz K.M., Knudsen A.B., Hundt S., Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer 2011, 104(11):1779-1785. [Epub 2011/05/12].
134. Brenner H., Haug U., Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010, 105(11):2457-2464. [Epub 2010/08/12].
135. Sadik R., Abrahamsson H., Stotzer P.O. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol 2003, 38(1):36-42. [Epub 2003/03/01].
136. Oort F.A., van Turenhout S.T., Coupe V.M., van der Hulst R.W., Wesdorp E.I., Terhaar sive Droste J.S., et al. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer 2011, 11:434. [Epub 2011/10/12].
137. Goede S.L., van Roon A.H.C., Reijerink J.C.I.Y., van Vuuren A.J., Lansdorp-Vogelaar I., Habbema J.D.F., et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2013, 62(5):727-734.
138. van Roon A.H.C., Goede S.L., van Ballegooijen M., van Vuuren A.J., Looman C.W.N., Biermann K., et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013, 62(3):409-415.
139. McDonald P.J., Digby J., Innes C., Strachan J.A., Carey F.A., Steele R.J., et al. Low faecal haemoglobin concentration potentially rules out significant colorectal disease. Colorectal Dis 2013, 15(3):e151-e159. [Epub 2012/12/04].
140. Digby J., Fraser C.G., Carey F.A., McDonald P.J., Strachan J.A., Diament R.H., et al. Faecal haemoglobin concentration is related to severity of colorectal neoplasia. J Clin Pathol 2013, 66(5):415-419. [Epub 2013/02/19].
141. Australian Government DoHaA Screening Retest Fact Sheet Available from:, [Accessed: 27/01/2014]. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/bw-retest.
142. Grazzini G., Ventura L., Zappa M., Ciatto S., Confortini M., Rapi S., et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 2010, 59(11):1511-1515. [Epub 2010/07/07].
143. van Roon A.H.C., Hol L., van Vuuren A.J., Francke J., Ouwendijk M., Heijens A., et al. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol 2012, 107(1):99-107.
144. Young G.P., Sinatra M.A., St John D.J. Influence of delay in stool sampling on fecal occult blood test sensitivity. Clin Chem 1996, 42(7):1107-1108.
145. Faure H., Exbrayat C., Winckel P., Bolla M. Moisture content of Hemoccult slides influences test sensitivity. Eur J Gastroenterol Hepatol 2003, 15(10):1111-1114. [Epub 2003/09/23].
146. Hunter J.P., Saratzis A., Froggatt P., Harmston C. Effect of season and ambient temperature on outcome of guaiac-based faecal occult blood tests performed for colorectal cancer screening. Colorectal Dis 2012, 14(9):1084-1089. [Epub 2011/11/30].
147. Seaman H.E., Butler P., Snowball J.M., Halloran S.P. PWE-020: Do seasonal trends in positivity exist with the guaiac-based faecal occult blood test?. Gut 2013, 62(Suppl. 1):A137-A138.
148. Rosenfield R.E., Kochwa S., Kaczera Z., Maimon J. Nonuniform distribution of occult blood in feces. Am J Clin Pathol 1979, 71(2):204-209.
149. Cole S.R., Young G.P., Esterman A., Cadd B., Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003, 10(3):117-122.
150. Ellis R.J., Wilson S., Holder R.L., McManus R.J. Different faecal sampling methods alter the acceptability of faecal occult blood testing: a cross sectional community survey. Eur J Cancer 2007, 43(9):1437-1444.
151. Weber M.F., Banks E., Ward R., Sitas F. Population characteristics related to colorectal cancer testing in New South Wales, Australia: results from the 45 and Up Study cohort. J Med Screen 2008, 15(3):137-142.
152. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 2001, 47(4):624-630.
153. Li R., Liu J., Xue H., Huang G. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis. Int J Cancer 2012, 131(8):1837-1845. [Epub 2012/01/21].
154. Rozen P., Knaani J., Papo N. Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia. Eur J Cancer Prev 1995, 4(6):475-481. [Epub 1995/12/01].
155. Hope R.L., Chu G., Hope A.H., Newcombe R.G., Gillespie P.E., Williams S.J. Comparison of three faecal occult blood tests in the detection of colorectal neoplasia. Gut 1996, 39(5):722-725.
156. Chen J.G., Cai J., Wu H.L., Xu H., Zhang Y.X., Chen C., et al. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test. World J Gastroenterol 2012, 18(21):2682-2688. [Epub 2012/06/13].
157. Tibble J., Sigthorsson G., Foster R., Sherwood R., Fagerhol M., Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001, 49(3):402-408.
158. Hoff G., Grotmol T., Thiis-Evensen E., Bretthauer M., Gondal G., Vatn M.H. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004, 53(9):1329-1333. [Epub 2004/08/13].
159. von Roon A.C., Karamountzos L., Purkayastha S., Reese G.E., Darzi A.W., Teare J.P., et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007, 102(4):803-813.
160. Kristinsson J., Armbruster C.H., Ugstad M., Kriwanek S., Nygaard K., Ton H., et al. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol 2001, 36(2):202-207. [Epub 2001/03/17].
161. Kronborg O., Ugstad M., Fuglerud P., Johne B., Hardcastle J., Scholefield J.H., et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000, 46(6):795-800. [Epub 2000/05/16].
162. Church T.R., Wandell M., Lofton-Day C., Mongin S.J., Burger M., Payne S.R., et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014, 63(2):317-325.
163. Payne S.R. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics 2010, 2(4):575-585. [Epub 2010/08/01].
164. Ahlquist D.A., Zou H., Domanico M., Mahoney D.W., Yab T.C., Taylor W.R., et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012, 142(2):248-256. [Epub 2011/11/09].
165. Kuipers E.J., Rosch T., Bretthauer M. Colorectal cancer screening - optimizing current strategies and new directions. Nat Rev Clin Oncol 2013, 10(3):130-142. [Epub 2013 Feb 5].
166. Imperiale T.F. Noninvasive screening tests for colorectal cancer. Dig Dis 2012, 30(Suppl. 2):16-26. [Epub 2012/12/12].
167. Reid G., Kirschner M.B., van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011, 80(2):193-208. [Epub 2010/12/15].
168. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Turnbull B.A., Ross M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004, 351(26):2704-2714.
169. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Levin T.R., Lavin P., Lidgard G.P., et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014, 370:1287-1297.
170. Robertson D.J., Dominitz J.A. Stool DNA and Colorectal-Cancer Screening. N Engl J Med 2014, 370:1350-1351.
171. Wang D.R., Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 2008, 14(4):524-531.
172. Young G.P., Cole S. New stool screening tests for colorectal cancer. Digestion 2007, 76(1):26-33. [Epub 2007/10/20].
173. Parekh M., Fendrick A.M., Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008, 27(8):697-712. [Epub 2008/02/06].
174. Haug U., Brenner H. New stool tests for colorectal cancer screening: a systematic review focusing on performance characteristics and practicalness. Int J Cancer 2005, 117(2):169-176.
175. Schwartz S., Dahl J., Ellefson M., Ahlquist D. The "HemoQuant" test: a specific and quantitative determination of heme (hemoglobin) in feces and other materials. Clin Chem 1983, 29(12):2061-2067.
176. Ahlquist D.A., McGill D.B., Schwartz S., Taylor W.F., Ellefson M., Owen R.A. HemoQuant, a new quantitative assay for fecal hemoglobin. Comparison with Hemoccult. Ann Intern Med 1984, 101(3):297-302.
177. Ahlquist D.A., McGill D.B., Schwartz S., Taylor W.F., Owen R.A. Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med 1985, 312(22):1422-1428.
178. Atkin W.S., Valori R., Kuipers E.J., Hoff G., Senore C., Segnan N., et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition - Colonoscopic surveillance following adenoma removal. Endoscopy 2012, 44(S 03):SE151-SE163.
179. Levin B., Lieberman D.A., McFarland B., Smith R.A., Brooks D., Andrews K.S., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008, 58(3):130-160. [Epub 2008/03/07].
180. Hazazi R., Rozen P., Leshno M., Levi Z., Samuel Z., Waked A., et al. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?. Aliment Pharmacol Ther 2010, 31(4):523-533. [Epub 2009/11/21].
181. Lane J.M., Chow E., Young G.P., Good N., Smith A., Bull J., et al. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 2010, 139(6):1918-1926.
182. Terhaar sive Droste J., van Turenhout S., Oort F., van der Hulst R., Steeman V., Coblijn U., et al. Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study. BMC Gastroenterol 2012, 12(1):94.
183. Kralj-Hans I., Martin J., Pearson S., Piggott C., Bowyer H., Vart G., et al. Could Faecal Immunochemical Tests for Haemoglobin (FIT) Change Surveillance of People with Intermediate Risk Adenomas? Abstract: PWE-023. Gut 2013, 62(Suppl. 1):A139.
184. Bowyer H., Vart G., Kralj-Hans I., Atkin W., Halloran S., Pearson S., et al. Patient attitudes towards faecal immunochemical testing for haemoglobin as an alternative to colonoscopy for surveillance of groups at higher risk of colorectal cancer. J Med Screen 2013, 20(3):149-156. [Epub 2013 Sep 17].
185. Benson V.S., Atkin W.S., Green J., Nadel M.R., Patnick J., Smith R.A., et al. Toward standardizing and reporting colorectal cancer screening indicators on an international level: The International Colorectal Cancer Screening Network. Int J Cancer 2012, 130(12):2961-2973. [Epub 2011/07/28].
186. Swan H., Siddiqui A.A., Myers R.E. International colorectal cancer screening programs: population contact strategies, testing methods and screening rates. Practical Gastroenterology 2012, 20-29. M. Schapiro (Ed.).
187. Zavoral M., Suchanek S., Zavada F., Dusek L., Muzik J., Seifert B., et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009, 15(47):5907-5915. [Epub 2009/12/17].
188. Regula J., Rupinski M., Kraszewska E., Polkowski M., Pachlewski J., Orlowska J., et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006, 355(18):1863-1872.
189. Gupta S., Tong L., Allison J.E., Carter E., Koch M., Rockey D.C., et al. Screening for colorectal cancer in a safety-net health care system: access to care is critical and has implications for screening policy. Cancer Epidemiol Biomarkers Prev 2009, 18(9):2373-2379. [Epub 2009/09/12].
190. Centers for Disease Control and Prevention Vital Signs: Colorectal Cancer Screening Test Use - United States, 2012 2013, Centers for Disease Control and Prevention, [Available from: http://www.cdc.gov/mmwr/pdf/wk/mm6244.pdf. Accessed 27-01-2014].
191. Regula J., Zagorowicz E., Butruk E. Implementation of a national colorectal cancer screening program. Curr Colorectal Cancer Rep 2006, 2(1):25-29.
192. Pox C.P., Altenhofen L., Brenner H., Theilmeier A., Von Stillfried D., Schmiegel W. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012, 142(7):1460-1467. [e2. Epub 2012/03/27].
193. Katicic M., Antoljak N., Kujundzic M., Stamenic V., Skoko Poljak D., Kramaric D., et al. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011). World J Gastroenterol 2012, 18(32):4300-4307. [Epub 2012/09/13].
194. Malila N., Palva T., Malminiemi O., Paimela H., Anttila A., Hakulinen T., et al. Coverage and performance of colorectal cancer screening with the faecal occult blood test in Finland. J Med Screen 2011, 18(1):18-23. [Epub 2011/05/04].
195. Public Health Wales NHS Trust Bowel Screening Wales Available from:, [Accessed: 27/01/2014]. http://www.wales.nhs.uk/sites3/home.cfm?orgid=747.
196. Portillo I., Idigoras I., Ojembarrena E., Arana E., Luis Hurtado J., Basurko R., et al. Lesions detected in a colorectal cancer screening program in the Basque Country: first round (2009-2011). Gastroenterol Hepatol 2013, 36(5):301-308. [Epub 2013/04/27. Lesiones detectadas en el programa de cribado de cancer colorrectal en el Pais Vasco: primera ronda 2009-2011].
197. Ministry of Health New Zealand Bowel screening pilot: January to June 2012 results Available from:, [Accessed: 27-01-2014]. http://www.health.govt.nz/our-work/diseases-and-conditions/cancer-programme/bowel-cancer-programme/bowel-screening-pilot/bowel-screening-pilot-results/bowel-screening-pilot-january-june-2012-results.
198. Australian Institute of Health and Welfare National Bowel Cancer Screening Program: July 2011 - June 2012 monitoring report 2013, Australian Institute of Health and Welfare, Canberra.
199. Cole S.R., Tucker G.R., Osborne J.M., Byrne S.E., Bampton P.A., Fraser R.J.L., et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust 2013, 198(6):327-330.
200. Ministry of Health Republic of Slovenia Screening for colorectal cancer (SVIT programme) Available from:, [Accessed: 27/01/2014]. http://www.dpor.si/en/?page_id=99.
201. Zorzi M., Fedato C., Grazzini G., Sassoli de' Bianchi P., Naldoni C., Pendenza M., et al. Screening for colorectal cancer in Italy, 2010 survey. Epidemiol Prev 2012, 36(6 Suppl. 1):55-77. [Epub 2013/01/11. Lo screening colorettale in Italia, survey 2010].
202. BowelScreen, The National Bowel Screening Programme, National Cancer Screening Service Available from:, [Accessed: 27-01-2014]. http://www.bowelscreen.ie/.
203. Saito H. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J Med Screen 2006, 13(Suppl. 1):S6-S7. [Epub 2007/01/18].
204. Shim J.I., Kim Y., Han M.A., Lee H.Y., Choi K.S., Jun J.K., et al. Results of colorectal cancer screening of the national cancer screening program in Korea, 2008. Cancer Res Treat J Korean Cancer Assoc 2010, 42(4):191-198. [Epub 2011/01/22].
205. Van Roosbroeck S., Hoeck S., Van Hal G. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: A comparison of two invitation strategies. Cancer Epidemiol 2012, 36(5):e317-e324. [Epub 2012/05/09].
206. Major D., Bryant H., Delaney M., Fekete S., Gentile L., Harrison M., et al. Colorectal cancer screening in Canada: results from the first round of screening for five provincial programs. Curr Oncol (Toronto, Ont) 2013, 20(5):252-257. [Epub 2013/10/25].
207. Suchanek S., Majek O., Vojtechova G., Minarikova P., Rotnaglova B., Seifert B., et al. Colorectal cancer prevention in the Czech Republic: time trends in performance indicators and current situation after 10years of screening. Eur J Cancer Prev 2014, 23(1).
208. Frederiksen B.L., Jorgensen T., Brasso K., Holten I., Osler M. Socioeconomic position and participation in colorectal cancer screening. Br J Cancer 2010, 103(10):1496-1501. [Epub 2010/10/21].
209. Leuraud K., Jezewski-Serra D., Viguier J., Salines E. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. Cancer Epidemiol 2013, 37(6):959-967.
210. Israel Cancer Association National Program for Early Detection of Colorectal Cancer Statistics Available from:, [Accessed: 27-01-2014]. http://en.cancer.org.il/template_e/default.aspx?PageId=7747.
211. National Institute for Public Health and the Environment Ministry of Health WaS. New bowel cancer screening programme Available from:, [Accessed: 27-01-2014]. http://www.rivm.nl/en/Topics/B/Bowel_cancer_screening_programme.
212. Norway CRo Bowel Cancer Screening in Norway - a pilot study Available from:, [Accessed: 27-01-2014]. http://www.kreftregisteret.no/en/Cancer-prevention/Screening-for-colorectal-cancer/.
213. Public Health England NHS Bowel Cancer Screening Programme Available from:, [Accessed: 27/01/2014]. http://www.cancerscreening.nhs.uk/bowel/.
214. Public Health Agency NI Quality Assurance Reference Centre (QARC) Available from:, [Accessed: 27/01/2014]. http://www.cancerscreening.hscni.net/2008.htm.
215. NHS Scotland Scottish Bowel Screening Programme Available from:, [Accessed: 27/01/2014]. http://www.bowelscreening.scot.nhs.uk/.
216. Inadomi J.M., Vijan S., Janz N.K., Fagerlin A., Thomas J.P., Lin Y.V., et al. Adherence to Colorectal Cancer Screening: A Randomized Clinical Trial of Competing Strategies. Arch Intern Med 2012, 172(7):575-582.
217. Levin T.R., Corley D.A. Colorectal-cancer screening-coming of age. N Engl J Med 2013, 369(12):1164-1166. [Epub 2013/09/21].
218. Stegeman I., de Wijkerslooth T.R., Stoop E.M., van Leerdam M.E., Dekker E., van Ballegooijen M., et al. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut 2013, 1-6. [Epub 2013/08/22].